Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06334432 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors

A Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor, sponsored by Nuvation Bio.

Active
Registry status
Phase 1
Development phase
466
Enrollment target
8
Study locations

NCT06334432 is a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor that is active but no longer recruiting, run by Nuvation Bio. The registered enrollment target is 466 participants, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (19% higher). The trial reports 8 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06334432, a Phase 1 study of Pancreatic Cancer and Advanced Solid Tumor, is active but no longer recruiting, sponsored by Nuvation Bio.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
466 participants
Enrollment target
8
Study locations

Study Summary

NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.

Conditions Studied

Pancreatic Cancer Advanced Solid Tumor HER2-Negative Breast Cancer Metastatic Castration-Resistant Prostate Cancer (mCRPC) Platinum-resistant Ovarian Cancer (PROC)

Interventions

  • DRUG NUV-1511

Study Locations (8)

Michigan

  • Karmanos Cancer Center - Detroit

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Memorial Sloan-Kettering Cancer Center - New York

North Carolina

  • Carolina BioOncology Institute - Huntersville

Texas

  • NEXT Oncology - Irving

Utah

  • START Mountain - Salt Lake City

Virginia

  • NEXT Oncology - Fairfax

Washington

  • Fred Hutchinson - Seattle

Trial Details

FieldValue
Enrollment Target 466 participants
Start Date 2024-03-14
Est. Completion 2027-10
Phase Phase 1

Sponsor

Nuvation Bio

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06334432

The ClinicalTrials.gov registry entry for NCT06334432 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 466 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (19% higher). The listed sponsor is Nuvation Bio, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which NUV-1511 is the first listed.

NCT06334432 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Michigan, New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT06334432 about?

NCT06334432 is a clinical study titled "Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors". NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase ...

What is the current status of trial NCT06334432?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 466 participants. The study started on 2024-03-14. Estimated completion is 2027-10.

What conditions does trial NCT06334432 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Solid Tumor, HER2-Negative Breast Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Platinum-resistant Ovarian Cancer (PROC).

What interventions are being tested in trial NCT06334432?

The interventions under investigation include: NUV-1511 (DRUG).

Who is sponsoring clinical trial NCT06334432?

This trial is sponsored by Nuvation Bio, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06334432 being conducted?

This trial has 8 study locations across Michigan, New Jersey, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Advanced Solid Tumor

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.